Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02071134 · ClinicalTrials.gov registry record
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
A clinical trial of Parkinson's Disease, sponsored by Boston Scientific Corporation.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 20
- Study locations
NCT02071134 is a study of Parkinson's Disease that is actively recruiting participants, run by Boston Scientific Corporation. The registered enrollment target is 1,500 participants, above the 633-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (137% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT02071134, a study of Parkinson's Disease, is actively recruiting participants, sponsored by Boston Scientific Corporation.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.
Conditions Studied
Interventions
- DEVICE Deep Brain Stimulation (DBS)
Study Locations (20)
Florida
- University of Florida Shands Hospital - Gainesville
- Mayo Clinic, Jacksonville - Jacksonville
- University of Miami Hospital - Miami
- Tallahassee Neurological Clinic, PA - Tallahassee
- University of South Florida - Tampa
New York
- Albany Medical College - Albany
- Northwell Health Neuroscience Institute - Great Neck
- University at Buffalo - Williamsville
California
- Neurology and Pain Specialty - Aliso Viejo
- Cedars Sinai Medical Center - Los Angeles
Colorado
- University of Colorado - Aurora
- St. Mary's Hospital and Medical Center - Grand Junction
Ohio
- Cleveland Clinic Foundation - Cleveland
- Ohio State University - Columbus
Idaho
- St. Luke Regional Medical Center - Boise
Illinois
- Rush University Medical Center - Chicago
Indiana
- Methodist Hospital of Indianapolis - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2014-03-04 |
| Est. Completion | 2038-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02071134
The ClinicalTrials.gov registry entry for NCT02071134 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 633-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (137% higher). The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which Deep Brain Stimulation (DBS) is the first listed.
NCT02071134 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, New York, California.
Frequently Asked Questions
What is clinical trial NCT02071134 about?
NCT02071134 is a clinical study titled "Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry". The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming fea...
What is the current status of trial NCT02071134?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2014-03-04. Estimated completion is 2038-12.
What conditions does trial NCT02071134 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT02071134?
The interventions under investigation include: Deep Brain Stimulation (DBS) (DEVICE).
Who is sponsoring clinical trial NCT02071134?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02071134 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease
RECRUITING · NA
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
Deep Brain Stimulation for Visuomotor Function in Parkinson's Disease
RECRUITING
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Feasibility and Safety of a Portable Exoskeleton to Improve Mobility in Parkinson's Disease
RECRUITING · NA
-
PET Imaging Evaluation of [11C]SY08
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.